Sunitix

12.5 mg

37.5 mg

25 mg

50 mg

Product Name: Sunitix
Generic Name: Sunitinib Malate
Dosage Forms: Capsules/Tablets
Available Strengths: 12.5 mg, 25 mg, 37.5 mg, 50 mg

Description:
Sunitix contains Sunitinib Malate, a multi-targeted receptor tyrosine kinase inhibitor used primarily in the treatment of certain types of cancers. It works by blocking specific enzymes that promote cancer cell growth and angiogenesis (the formation of new blood vessels that feed tumors).

Indications:

• Advanced renal cell carcinoma (RCC)

• Gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib

• Pancreatic neuroendocrine tumors (pNET)

Mechanism of Action:
Sunitinib inhibits multiple receptor tyrosine kinases, including VEGFR, PDGFR, KIT, FLT3, CSF-1R, and RET, leading to reduced tumor vascularization and cancer cell proliferation.

Key Features:

• Broad-spectrum activity against tumor growth pathways

• Oral administration for patient convenience

• Used in first-line and subsequent-line therapy of specific cancers

Packaging:
Blister packs or bottles (packaging may vary by strength and regulatory market).

Storage:
Store at 20°C to 25°C (68°F to 77°F); protect from moisture and light.

Note:
Sunitix should be used under the supervision of an oncologist. Patients should be monitored regularly for side effects, including hypertension, fatigue, and gastrointestinal symptoms.